MOA Life Plus Co Ltd 142760
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- KRW 3,570.00
- Day Range
- KRW 3,535.00–3,845.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 3,825.00 / KRW 3,830.00
- Market Cap
- KRW 144.52 Bil
- Volume/Avg
- 884 / 688,170
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MOA Life Plus Co Ltd engages in the research and development of healthcare products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 45
- Website
- http://www.bioleaders.co.kr
Comparables
Valuation
|
Metric
|
142760
|
321550
|
302440
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 412.70 |
Price/Book Value | 3.68 | 2.94 | 2.59 |
Price/Sales | 5.80 | 35.45 | 11.98 |
Price/Cash Flow | — | — | 92.76 |
Price/Earnings
142760
321550
302440
Financial Strength
|
Metric
|
142760
|
321550
|
302440
|
|---|---|---|---|
Quick Ratio | 2.19 | 3.67 | 9.56 |
Current Ratio | 2.38 | 3.88 | 10.20 |
Interest Coverage | −3.02 | −7.20 | −3.45 |
Quick Ratio
142760
321550
302440
Profitability
|
Metric
|
142760
|
321550
|
302440
|
|---|---|---|---|
Return on Assets (Normalized) | −1.89% | −15.28% | 2.49% |
Return on Equity (Normalized) | −11.35% | −34.91% | 2.86% |
Return on Invested Capital (Normalized) | −1.56% | −17.65% | 2.26% |
Return on Assets
142760
321550
302440
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lfskxykqc | Hqvb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vcnnbpsy | Fdplzw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wzmqtcw | Gztml | $97.8 Bil | |
MRNA
| Moderna Inc | Vvzvyfss | Vxdc | $38.8 Bil | |
ARGX
| argenx SE ADR | Vpzdxcjw | Vfxy | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Ghtbtfd | Ygqpw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jmfsglrc | Tddnhhj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gfgskkkd | Dgprdy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wwtlwwvrch | Pgxtst | $12.5 Bil | |
INCY
| Incyte Corp | Xghmtwhsw | Phtxgh | $11.5 Bil |